PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
| Autor: | Hideto Tamura, Mariko Ishibashi, Mika Sunakawa-Kii, Koiti Inokuchi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research monoclonal gammopathy of undetermined significance (MGUS) Review lcsh:RC254-282 Asymptomatic immune checkpoint inhibitors 03 medical and health sciences 0302 clinical medicine Downregulation and upregulation Refractory PD-L1 (B7-H1) PD-L1 hemic and lymphatic diseases PD-1 medicine PI3K/AKT/mTOR pathway Multiple myeloma biology business.industry lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Pathophysiology multiple myeloma 030104 developmental biology AKT pathway Oncology 030220 oncology & carcinogenesis Cancer research biology.protein medicine.symptom business Monoclonal gammopathy of undetermined significance |
| Zdroj: | Cancers Cancers, Vol 12, Iss 924, p 924 (2020) |
| ISSN: | 2072-6694 |
| Popis: | PD-L1 expressed on tumor cells contributes to disease progression with evasion from tumor immunity. Plasma cells from multiple myeloma (MM) patients expressed higher levels of PD-L1 compared with healthy volunteers and monoclonal gammopathy of undetermined significance (MGUS) patients, and its expression is significantly upregulated in relapsed/refractory patients. Furthermore, high PD-L1 expression is induced by the myeloma microenvironment and PD-L1+ patients with MGUS and asymptomatic MM tend to show disease progression. PD-L1 expression on myeloma cells was associated with more proliferative potential and resistance to antimyeloma agents because of activation of the Akt pathway through PD-1-bound PD-L1 in MM cells. Those data suggest that PD-L1 plays a crucial role in the disease progression of MM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |